To evaluate the preliminary efficacy of a multicomponent adherence intervention focused on enhancing digital equity and pharmaco-equity among nonadherent patients with metastatic breast cancer (MBC) and cardiovascular disease (CVD) risk factors on endocrine therapy (ET), CDK4/6 inhibitor (CDK 4/6i), and CVD medications. To assess the acceptability and appropriateness of this intervention in patients with MBC and CVD risk factors through validated measures of implementation outcomes. To gain a deeper understanding of the impact of social determinants of health (SDOH) on medication nonadherence through semi-structured interviews with a subset of study participants.
Women or men age >18 years Diagnosed with stage IV/metastatic breast cancer prescribed endocrine therapy and a CDK4/6i Prescribed at least 1 antihypertensive or statin medication for CVD prevention or treatment Self-report of at least some nonadherence ET/CDK4/6i or CVD medication on nonadherence screener or verbally to a treating clinician, or nonadherent to ET, CDK4/6i, and/or CVD medication on pharmacy fill data in the EHR (proportion of days covered over prior 180 days <80%).
Exclusion Criteria:
Non-English or Non-Spanish speaking Not cognitively able to complete study requirements Inability to provide informed consent for any other reason (e.g, severe psychiatric illness, active substance use) Unavailable for 28 weeks of follow-up
